Related Experiment Video
Updated: Jun 14, 2026
07:43
A Simple Approach to Perform TEER Measurements Using a Self-Made Volt-Amperemeter with Programmable Output Frequency
Published on: October 5, 2019
Comparison of CE approved TEVAR devices.
1Department of Vascular Surgery, University of Cologne, Cologne, Germany. michael.gawenda@uk-koeln.de
The Journal of Cardiovascular Surgery
|April 1, 2010
Summary
Endovascular therapy for thoracic aortic pathologies is growing, presenting complex challenges in stent graft delivery and fixation. Evaluating new thoracic stent grafts is difficult due to evolving indications and limited clinical trial data.
Area of Science:
- Cardiovascular Surgery
- Endovascular Interventions
- Medical Device Technology
Background:
- Indications for endovascular therapy of thoracic aortic pathologies are expanding.
- Increasing case complexity presents challenges in stent graft delivery, deployment, and fixation.
- Individual patient anatomy and aortic pathology contribute to procedural difficulties.
Purpose of the Study:
- To review the current landscape of thoracic stent graft devices available in Europe.
- To discuss the challenges in assessing the efficacy and safety of new stent graft iterations.
- To highlight the need for robust clinical data to support the use of evolving thoracic endografts.
Main Methods:
- Review of available clinical data and device iterations for thoracic stent grafts in Europe.
- Analysis of challenges related to stent graft delivery, deployment, and fixation in complex aortic anatomies.
- Discussion of the impact of changing indications and limited large-scale trials on device assessment.
Main Results:
- Several new iterations of thoracic stent grafts have been introduced into clinical practice.
- Variable amounts of clinical data exist to support the use of currently available devices.
- Assessment of new grafts is hindered by evolving indications and a lack of extensive clinical trials.
Conclusions:
- The field of endovascular thoracic aortic repair is rapidly advancing.
- Challenges in device delivery, deployment, and fixation persist.
- Further large-scale clinical trials are needed to adequately assess new thoracic stent graft technologies.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
00:51Non-ohmic Devices
In most substances, the current flow is proportional to the voltage applied to it. A simple relationship between the values of current, voltage, and resistance is known as Ohm's law. Nonohmic devices do not exhibit a linear relationship between voltage and current. One such device is the semiconducting circuit element known as a diode. A diode is a circuit device that allows current flow in only one direction.
Consider a simple circuit consisting of a battery, a diode, and a resistor. A diode...
Consider a simple circuit consisting of a battery, a diode, and a resistor. A diode...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.